Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 80.49% | 87.75% | -32.85% | -59.99% | -78.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.49% | 87.75% | -32.85% | -59.99% | -78.32% |
| Cost of Revenue | 11.78% | 32.71% | 17.59% | -15.01% | -51.45% |
| Gross Profit | 106.11% | 76.58% | -269.55% | -148.65% | -143.11% |
| SG&A Expenses | -40.61% | 427.17% | 387.02% | 312.05% | 316.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.01% | 130.97% | 74.24% | 29.40% | 4.64% |
| Operating Income | 53.23% | -174.09% | -3,953.74% | -355.10% | -494.87% |
| Income Before Tax | 59.68% | -15.67% | -147.02% | -827.40% | -1,439.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.68% | -15.67% | -147.02% | -827.40% | -1,439.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.68% | -15.67% | -147.02% | -827.40% | -1,439.28% |
| EBIT | 53.23% | -174.09% | -3,953.74% | -355.10% | -494.87% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 60.24% | -13.22% | -138.42% | -738.18% | -1,420.45% |
| Normalized Basic EPS | 59.94% | -13.36% | -139.68% | -744.12% | -1,440.74% |
| EPS Diluted | 60.24% | -13.22% | -138.42% | -598.48% | -1,860.61% |
| Normalized Diluted EPS | 59.94% | -13.36% | -139.68% | -617.50% | -1,823.81% |
| Average Basic Shares Outstanding | 1.11% | 1.21% | 1.44% | 1.67% | 0.29% |
| Average Diluted Shares Outstanding | 1.11% | 1.21% | 1.44% | -0.52% | -1.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
